FDA approves bevacizumab-bvzr for several cancersJune 28, 2019Gynecologic CancerRenal Cell CarcinomaLung CancerGastroenterologyGenitourinary CancerCNS/Brain CancerNeuro-oncology
Nephrectomy may benefit select renal cancer patients based on risk factorsJune 5, 2019Renal Cell CarcinomaGenitourinary Cancer
Trial matches pediatric cancer patients to targeted therapiesMay 31, 2019Sarcoma & GISTPediatricsRenal Cell CarcinomaCNS/Brain CancerGenitourinary Cancer
Model shows nivolumab plus ipilimumab cost effective in mRCCFebruary 25, 2019Practice ManagementGenitourinary CancerRenal Cell CarcinomaImmuno-oncology
First-line avelumab/axitinib for RCC benefits wide range of patientsFebruary 21, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Pembrolizumab-axitinib nearly halves risk of death in RCCFebruary 12, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Severe adverse events seen in placebo arm of cancer clinical trialsDecember 13, 2018Immuno-oncologyRenal Cell Carcinoma
‘Optimal’ pazopanib levels linked to lower toxicity in RCC patientsDecember 13, 2018Renal Cell CarcinomaGenitourinary Cancer
Cytoreductive nephrectomy may benefit RCC patients with brain metsDecember 12, 2018Renal Cell CarcinomaGenitourinary Cancer
Lipoprotein ratio linked to poor survival in metastatic RCCDecember 11, 2018Renal Cell CarcinomaGenitourinary Cancer
RCC strongly linked to melanoma, and vice versaDecember 10, 2018Renal Cell CarcinomaGenitourinary CancerMelanoma
RCC research has opened door to the future, but “much work remains to be done”December 5, 2018Renal Cell Carcinoma
hTERT expression predicts RCC survival, tumor aggressivenessDecember 4, 2018Renal Cell CarcinomaGenitourinary Cancer
Age-related gene expression may affect responses to RCC therapyDecember 4, 2018Renal Cell CarcinomaImmunotherapyGenitourinary CancerImmuno-oncology
